Business Context and Reporting Period
Company: AnaptysBio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2018 (Earliest event reported)
Reporting Period Covered: Quarter and year ended December 31, 2017
Context: The filing announces financial results for the period ended December 31, 2017, and reports changes in the Board of Directors.
Key Financial Metrics
This Form 8-K serves as a notification of financial results but does not contain specific numerical data within the text provided. The actual revenue, profit, cash flow, margins, debt, and liquidity figures are contained in the attached press release (Exhibit 99.01), which is not included in the source text. Therefore, the filing text does not provide a clear value for these metrics.
Material Changes
Board of Directors Changes:
- Resignation: Carol G. Gallagher, Pharm. D., resigned as a Class I independent director and member of the audit and compensation committees, effective March 5, 2018. The resignation was not due to any disagreement with the company.
- Appointments: J. Anthony Ware, M.D., was appointed to the audit committee, and Dennis Fenton, Ph.D., was appointed to the compensation committee.
- Election: Dennis Fenton, Ph.D., was elected to the Board to fill the vacancy created by Ms. Gallagher's resignation. He serves as a Class I director until the 2018 Annual Meeting.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release regarding financial results but does not include specific management commentary, guidance, or outlook within the text.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text. The filing notes that the financial information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other documents unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.01 (Press Release) for specific revenue, net loss, and cash position figures for the year ended December 31, 2017.
- Verify the qualifications and independence status of the newly elected director, Dennis Fenton, Ph.D.
- Confirm the compensation structure for the new director, including the pro-rated annual grant for 2018.
- Monitor the company's cash burn rate and runway, as the filing indicates the company is an emerging growth company with no reported revenue in the text.